Insulin products sold in Minnesota cost review authorized by commissioner of health, excessive cost determined, maximum level of reimbursement established for insulin products if necessary, and money appropriated. This bill establishes a process for the commissioner of health to review the cost of insulin products made available for sale in the state, determine if the cost of a product has led or
will lead to excess costs for health care systems in the state, and establish a maximum level of reimbursement for an insulin product that the commissioner finds has led or will
lead to excess costs for health care systems. Excess cost is defined as a cost that is not sustainable to public and private health care systems over a ten-year period.